Peter M. DiBattiste, M.D. is responsible for co-leading the Cardiovascular & Metabolism (CVM) Therapeutic Area at Janssen Research & Development, setting the strategy and leading the team in discovery and development of novel therapeutics for cardiovascular disease. He is focused on further establishing the company’s presence in thrombosis and heart failure by strategically broadening the portfolio through both internal and external innovation.
Peter joined the Johnson & Johnson Family of Companies in 2005 as Vice President, Cardiology, and later served as Vice President, Development Head, Cardiovascular and Urology.
Prior to joining the Johnson & Johnson Family of Companies, Peter held the position of Executive Director, Cardiovascular Clinical Research at AstraZeneca, overseeing the United States arm of the company’s portfolio of projects in the areas of diabetes, thrombosis, heart failure, hypertension and dyslipidemia. He also spent six years at Merck in both Medical Affairs and Cardiovascular R&D. Before joining Merck, he practiced medicine for 10 years as an interventional cardiologist.
Peter earned his M.D. at Harvard Medical School in Boston, Massachusetts. He completed his internal medicine residency at the University of Texas Southwestern in Dallas, Texas, and his fellowship in cardiovascular disease at the University of Pennsylvania in Philadelphia, Pennsylvania.